ME03713B - Bardoksolon meтil za lečenje gojaznosтi - Google Patents
Bardoksolon meтil za lečenje gojaznosтiInfo
- Publication number
- ME03713B ME03713B MEP-2020-4A MEP420A ME03713B ME 03713 B ME03713 B ME 03713B ME P420 A MEP420 A ME P420A ME 03713 B ME03713 B ME 03713B
- Authority
- ME
- Montenegro
- Prior art keywords
- patient
- compound
- use according
- disease
- diagnosed
- Prior art date
Links
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 229910016523 CuKa Inorganic materials 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000013585 weight reducing agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (21)
1. Jedinjenje iz formule: za upotrebu za terapijsko smanjenje tei:ine humanog pacijenta kom je potrebno.
2. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu:(a) pacijentu nije dijagnostikovano hronicno oboljenje bubrega (CKO); iii(b) pacijentu nije dijagnostikovana dijabetesna nefropatija (ON).
3. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu: (a) pacijent nema hronicno oboljenje bubrega (CKO);(b) pacijent ne boluje od renalnog oboljenja; iii(c) pacijent nema dijabetesnu nefropatiju (ON).
4.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu: (a) pacijentu nije dijagnostikovan dijabetes;(b) pacijentu nije dijagnostikovana insulinska rezistencija; iii(c) pacijentu nije dijagnostikovana netolerancija na glukozu.
5.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu:(a) pacijent nema dijabetes;(b) pacijent nema insulinsku rezistenciju; iii1(c) pacijent nema netoleranciju na glukozu.
6.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijentu nije dijagnostikovano kardiovaskularno oboljenje.
7.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema kardiovaskularno oboljenje.
8.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijentu nije dijagnostikovano oboljenje masne jetre.
9.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema oboljenje masne jetre.
10. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema povisene nivoe barem jednog biomarkera povezanog sa metabolickim sindromom.
11.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijentu nije dijagnostikovan kancer.
12.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema kancer.
13.Jedinjenje za upotrebu prerna patentnom zahtevu 1, pri cemu:(a) pacijent ne boluje od autoimunog oboljenja; (b) pacijent ne boluje od respiratornog oboljenja;(c) pacijent ne boluje od neurodegenerativnog oboljenja; (d) pacijent ne boluje od bolesti jetre; iii(e) pacijent ne boluje od infektivne bolesti.
14.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu je pacijent gojazan.
15. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu je barem deo jedinjenja prisutan kao amorfni oblik koji ima obrazac rendgenske difrakcije(CuKa) sa halo vrsnom vrednoscu na priblizno 13,5 °29, i Tg od oko 120 oc dooko 135 °C.
16. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 1 do 15, pri cemu se to jedinjenje isporucuje u dnevnoj dozi od 5 mg do 50 mg.
17.Jedinjenje za upotrebu prema patentnom zahtevu 16, pri cemu je ta dnevna doza oko 10 mg, oko 20 mg, iii oko 40 mg.
18. Upotreba jedinjenja kako je definisano u patentnom zahtevu 1 iii patentnom zahtevu 15 za proizvodnju leka za terapijsko smanjenje tezine humanog pacijenta kako je definisano u bilo kom od patentnih zahteva 1 do 14.
19. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu je to jedinjenje formulisano kao disperzija u cvrstom obliku koja obuhvata jedinjenje iz patentnog zahteva 1 i neki ekscipijent.
20. Jedinjenje za upotrebu prema patentnom zahtevu 19, pri cemu je taj ekscipijent metakrilna kiselina -etil akrilat kopolimer.
21.Jedinjenje za upotrebu prema patentnom zahtevu 20, pri cemu je odnos u metakrilna kiselina -etil akrilat kopolimeru 1:1.3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32327610P | 2010-04-12 | 2010-04-12 | |
| US38909010P | 2010-10-01 | 2010-10-01 | |
| PCT/US2011/032156 WO2011130302A2 (en) | 2010-04-12 | 2011-04-12 | Method of treating obesity using antioxidant inflammation modulators |
| EP11715645.5A EP2558105B1 (en) | 2010-04-12 | 2011-04-12 | Bardoxolone methyl for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03713B true ME03713B (me) | 2021-01-20 |
Family
ID=44259866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-4A ME03713B (me) | 2010-04-12 | 2011-04-12 | Bardoksolon meтil za lečenje gojaznosтi |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10105372B2 (me) |
| EP (1) | EP2558105B1 (me) |
| JP (1) | JP5990160B2 (me) |
| KR (1) | KR101819699B1 (me) |
| CN (1) | CN102939089B (me) |
| AU (1) | AU2011240690C1 (me) |
| BR (1) | BR112012026112B1 (me) |
| CA (1) | CA2795320C (me) |
| CL (1) | CL2012002859A1 (me) |
| CY (1) | CY1122480T1 (me) |
| DK (1) | DK2558105T3 (me) |
| EA (1) | EA026567B1 (me) |
| ES (1) | ES2768204T3 (me) |
| HR (1) | HRP20192291T1 (me) |
| HU (1) | HUE047994T2 (me) |
| IL (1) | IL222273B (me) |
| LT (1) | LT2558105T (me) |
| ME (1) | ME03713B (me) |
| MX (1) | MX357596B (me) |
| MY (1) | MY163031A (me) |
| NZ (1) | NZ602826A (me) |
| PH (1) | PH12012502041B1 (me) |
| PL (1) | PL2558105T3 (me) |
| PT (1) | PT2558105T (me) |
| RS (1) | RS59850B1 (me) |
| SG (2) | SG10201808661XA (me) |
| SI (1) | SI2558105T1 (me) |
| SM (1) | SMT202000086T1 (me) |
| TW (1) | TWI558724B (me) |
| WO (1) | WO2011130302A2 (me) |
| ZA (1) | ZA201207518B (me) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| TWI492745B (zh) | 2008-01-11 | 2015-07-21 | Reata Pharmaceuticals Inc | 合成的三萜系化合物及其使用於治療疾病之方法 |
| WO2009129548A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
| EA022588B1 (ru) | 2008-04-18 | 2016-01-29 | Ритэ Фамэсутикл, Инк. | Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце |
| DK2276493T3 (da) | 2008-04-18 | 2019-01-02 | Reata Pharmaceuticals Inc | Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17 |
| MX2010011435A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
| AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| ME03713B (me) | 2010-04-12 | 2021-01-20 | Reata Pharmaceuticals Inc | Bardoksolon meтil za lečenje gojaznosтi |
| NZ612788A (en) | 2010-12-17 | 2015-10-30 | Reata Pharmaceuticals Inc | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| EP2683731B1 (en) | 2011-03-11 | 2019-04-24 | Reata Pharmaceuticals, Inc. | C4-monomethyl triterpenoid derivatives and methods of use thereof |
| KR101174701B1 (ko) * | 2011-12-29 | 2012-08-17 | 서울대학교산학협력단 | 진저레논 에이를 포함하는 비만 예방용 식품 조성물, 비만 치료용 약학조성물 및 비만 치료용 동물용 의약품 |
| SI3444261T1 (sl) | 2012-04-27 | 2021-04-30 | Reata Pharmaceuticals, Inc. | 2,2-difluoropropionamidni derivat bardoksolon metila, njegovi farmacevtski sestavki in polimorfi za uporabo pri zdravljenju določenih stanj |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| EP2892910B1 (en) * | 2012-09-10 | 2016-09-07 | AbbVie Inc. | Glycyrrhetinic acid derivatives with anti-inflammatory activity |
| PL2892912T3 (pl) | 2012-09-10 | 2019-10-31 | Reata Pharmaceuticals Inc | C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| HUE040496T2 (hu) | 2012-09-27 | 2019-03-28 | Childrens Medical Ct Corp | Vegyületek elhízás kezelésére és alkalmazási eljárásaik |
| WO2014148455A1 (ja) | 2013-03-19 | 2014-09-25 | 第一三共株式会社 | テルペノイド誘導体 |
| UY35534A (es) | 2013-04-24 | 2014-10-31 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| PH12016500358B1 (en) * | 2013-08-23 | 2023-08-16 | Reata Pharmaceuticals Inc | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| MX372772B (es) | 2014-01-24 | 2020-06-29 | Reata Pharmaceuticals Inc | Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes. |
| US10155003B2 (en) * | 2014-05-05 | 2018-12-18 | The Board Of Regents Of The University Of Texas System | Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer |
| ES2770772T3 (es) | 2014-09-10 | 2020-07-03 | Daiichi Sankyo Co Ltd | Composición farmacéutica de liberación sostenida para el tratamiento y prevención de enfermedades oculares |
| NZ734292A (en) | 2015-02-12 | 2022-09-30 | Reata Pharmaceuticals Inc | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| CN105017374B (zh) * | 2015-07-20 | 2017-03-01 | 山西大学 | 一种齐墩果酸内酯类衍生物及其制备方法和应用 |
| US20170056373A1 (en) * | 2015-09-01 | 2017-03-02 | Syracuse University | Ghrelin o-acyltransferase inhibitors |
| MX386256B (es) | 2015-09-23 | 2025-03-18 | Reata Pharmaceuticals Inc | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. |
| JP7012379B2 (ja) | 2016-09-08 | 2022-01-28 | レジネラ ファーマ リミテッド | 視神経症を処置するためのトリテルペノイドを含む組成物およびその使用 |
| MX2019005401A (es) | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| IL279348B2 (en) | 2018-06-15 | 2026-01-01 | Reata Pharmaceuticals Inc | Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| WO2021016191A1 (en) | 2019-07-19 | 2021-01-28 | Reata Pharmaceuticals, Inc. | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof |
| JP2023524035A (ja) * | 2020-04-29 | 2023-06-08 | バイオエイジ ラブス， インコーポレイテッド | 加齢性状態を処置するための低酸素誘導因子プロリルヒドロキシラーゼ阻害剤 |
| CN115803059A (zh) * | 2020-05-09 | 2023-03-14 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗covid-19的方法 |
| WO2024145502A1 (en) * | 2022-12-29 | 2024-07-04 | The Board Of Regents Of The University Of Texas System | Synthetic triterpenoids and compositions thereof in weight management, skeletal muscle function, and appetite suppression |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| EP1591437B1 (en) | 1999-05-14 | 2009-11-25 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| US6890946B2 (en) | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| EP1322661A1 (en) | 2000-09-29 | 2003-07-02 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| AU2002243246A1 (en) | 2000-11-28 | 2002-06-24 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| WO2002076472A2 (en) * | 2001-03-23 | 2002-10-03 | Shire Biochem Inc. | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
| AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
| DK1465615T3 (da) | 2002-01-15 | 2012-11-12 | Dartmouth College | Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf |
| US6974801B2 (en) * | 2002-05-13 | 2005-12-13 | The Trustees Of Dartmounth College | Inhibitors and methods of use thereof |
| EP1457206A1 (en) | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Combined use of a fibrate and orlistat for the treatment of obesity |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| EP1625158A2 (en) | 2003-05-09 | 2006-02-15 | Novo Nordisk A/S | Peptides for use in treating obesity |
| RU2005133970A (ru) * | 2003-05-09 | 2007-06-20 | Ново Нордиск А/С (DK) | Пептиды, применяемые для лечения ожирения |
| CN103211806B (zh) | 2003-05-27 | 2015-09-09 | 帝斯曼知识产权资产管理有限公司 | 新颖的营养药物性组合物及其用途 |
| WO2006029221A2 (en) | 2004-09-07 | 2006-03-16 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| WO2005046732A2 (en) | 2003-11-04 | 2005-05-26 | THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH | Methods and compositions for the inhibition of hiv-1 replication |
| BRPI0417987A (pt) | 2003-12-22 | 2007-04-27 | Alcon Inc | agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| WO2005113761A2 (en) | 2004-04-19 | 2005-12-01 | University Of Maryland, Baltimore | Novel alanine transaminase enzymes and methods of use |
| US7772195B2 (en) | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| WO2007005879A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| US20070249561A1 (en) | 2006-04-25 | 2007-10-25 | Taylor Bradley K | Pharmacological method for treatment of neuropathic pain |
| WO2008000068A1 (en) | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Method for preparing 2-iodo triterpenoid compounds |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| CA2670099A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US20090048205A1 (en) | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| US9012439B2 (en) | 2007-10-29 | 2015-04-21 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| TWI492745B (zh) * | 2008-01-11 | 2015-07-21 | Reata Pharmaceuticals Inc | 合成的三萜系化合物及其使用於治療疾病之方法 |
| TW201004627A (en) * | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| MX2010011435A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
| DK2276493T3 (da) | 2008-04-18 | 2019-01-02 | Reata Pharmaceuticals Inc | Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17 |
| WO2009129548A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
| EA022588B1 (ru) | 2008-04-18 | 2016-01-29 | Ритэ Фамэсутикл, Инк. | Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце |
| AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| ES2731601T3 (es) | 2009-02-13 | 2019-11-18 | Reata Pharmaceuticals Inc | Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo |
| ME03713B (me) | 2010-04-12 | 2021-01-20 | Reata Pharmaceuticals Inc | Bardoksolon meтil za lečenje gojaznosтi |
| US8618125B2 (en) | 2011-01-14 | 2013-12-31 | Heptiva LLC | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance |
| CN102875634B (zh) | 2012-10-24 | 2014-08-20 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 |
| CN102887936A (zh) | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
-
2011
- 2011-04-12 ME MEP-2020-4A patent/ME03713B/me unknown
- 2011-04-12 PH PH1/2012/502041A patent/PH12012502041B1/en unknown
- 2011-04-12 SM SM20200086T patent/SMT202000086T1/it unknown
- 2011-04-12 PT PT117156455T patent/PT2558105T/pt unknown
- 2011-04-12 MX MX2012011892A patent/MX357596B/es active IP Right Grant
- 2011-04-12 ES ES11715645T patent/ES2768204T3/es active Active
- 2011-04-12 CN CN201180028997.6A patent/CN102939089B/zh active Active
- 2011-04-12 RS RS20200073A patent/RS59850B1/sr unknown
- 2011-04-12 MY MYPI2012004530A patent/MY163031A/en unknown
- 2011-04-12 BR BR112012026112-6A patent/BR112012026112B1/pt active IP Right Grant
- 2011-04-12 SI SI201131840T patent/SI2558105T1/sl unknown
- 2011-04-12 HR HRP20192291TT patent/HRP20192291T1/hr unknown
- 2011-04-12 EP EP11715645.5A patent/EP2558105B1/en active Active
- 2011-04-12 US US13/085,338 patent/US10105372B2/en active Active
- 2011-04-12 LT LTEP11715645.5T patent/LT2558105T/lt unknown
- 2011-04-12 AU AU2011240690A patent/AU2011240690C1/en active Active
- 2011-04-12 WO PCT/US2011/032156 patent/WO2011130302A2/en not_active Ceased
- 2011-04-12 DK DK11715645.5T patent/DK2558105T3/da active
- 2011-04-12 TW TW100112717A patent/TWI558724B/zh not_active IP Right Cessation
- 2011-04-12 JP JP2013505061A patent/JP5990160B2/ja active Active
- 2011-04-12 SG SG10201808661XA patent/SG10201808661XA/en unknown
- 2011-04-12 NZ NZ602826A patent/NZ602826A/en unknown
- 2011-04-12 PL PL11715645T patent/PL2558105T3/pl unknown
- 2011-04-12 SG SG2012075834A patent/SG184830A1/en unknown
- 2011-04-12 EA EA201291031A patent/EA026567B1/ru not_active IP Right Cessation
- 2011-04-12 HU HUE11715645A patent/HUE047994T2/hu unknown
- 2011-04-12 CA CA2795320A patent/CA2795320C/en active Active
- 2011-04-12 KR KR1020127029558A patent/KR101819699B1/ko active Active
-
2012
- 2012-10-08 ZA ZA2012/07518A patent/ZA201207518B/en unknown
- 2012-10-09 IL IL222273A patent/IL222273B/en active IP Right Grant
- 2012-10-12 CL CL2012002859A patent/CL2012002859A1/es unknown
-
2018
- 2018-09-13 US US16/130,242 patent/US11911395B2/en active Active
-
2020
- 2020-01-09 CY CY20201100022T patent/CY1122480T1/el unknown
-
2024
- 2024-02-26 US US18/587,006 patent/US20240335457A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03713B (me) | Bardoksolon meтil za lečenje gojaznosтi | |
| JP2011527332A5 (me) | ||
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| JP2013525444A5 (me) | ||
| HRP20250732T1 (hr) | Kombinacija derivata 4-pirimidinsulfamida sa sglt-2 inhibitorom za liječenje bolesti povezanih s endotelinom | |
| RU2017130849A (ru) | Дейтерированная производная хенодезоксихолевой кислоты и фармацевтическая композиция, содержащая данное соединение | |
| JP2012509348A5 (me) | ||
| JP2007504174A5 (me) | ||
| JP2018529779A5 (me) | ||
| JP2011513307A5 (me) | ||
| IL297844A (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids | |
| RU2010143864A (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| RU2009135016A (ru) | Твердые формы, содержащие (-)-о-десметилвенлафаксин, и их применения | |
| JP2009537554A5 (me) | ||
| JP2009538898A5 (me) | ||
| JP2010513229A5 (me) | ||
| JP2010520200A5 (me) | ||
| CA2648518A1 (en) | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor | |
| JP2013544244A5 (me) | ||
| JP2015514797A5 (me) | ||
| JP2017014206A5 (me) | ||
| JP2016521279A5 (me) | ||
| JP2011521962A5 (me) | ||
| JP2010024244A5 (me) | ||
| JP2012506429A5 (me) |